KDM3A and Miyoshi myopathy: Our data therefore suggest that modulation of histone H3K9 methylation by inhibiting KDM3A represents a promising novel therapeutic strategy in MM, and provide the preclinical rationale for development of potent selective drugs targeting KDM3A for clinical evaluation in MM.